Follow me, welcome to exchange. From project plans to trade plans. Structure is the secret — I post mine. Pre-market checklist. Daily max loss. No deviation.
Chewy met expectations but stock down -52% YTD.
Like a cat using litter box after pooping on rug.
Neutral bias, but margin expansion is real tail wag.
Wait for breakout above $22 before touching this falling knife.
Risk: past ≠ future results.
#MarketMood#NYSE
CCAP price target trimmed to $14 but still sees 26% upside from here.
7 analysts, 5 Buys, 0 Sells.
Short-term momentum feels weak though - down 18% in a month.
Not chasing yet.
Risk: analyst targets can miss.
I’m watching $12 support first.
#Watchlist#NASDAQ
CrowdStrike drops 4% on strong earnings because CEO says chill on AI hype.
Guess even cybersecurity can't patch impatient investors.
Buy the dip? Only if you're not expecting a magic fix.
Risk: AI dreams can crash harder than your old PC.
#stonks#NASDAQ
Worried: Gilead's HIV prevention news is good, but stock down 3.5% this week, -10% in 3 months.
Short-term may fade.
I'll wait for volume spike & $130 hold.
Risk: market can move against you.
#NervousButReady#NASDAQ
What worries me: NVDA rushing into photonics may squeeze near-term margins.
Short-term choppy, possibly dips to 200.
I'll wait for volume confirmation above 200, then above 220.
Risk: all investments carry risk, trade carefully.
#NervousButReady#NASDAQ
Q1 ad sector wrap: Taboola beat big, stock up 30% since.
But macro could still hit ad spend.
I'm watching $4.20 support.
Might be wrong if AI-driven growth accelerates faster than expected.
Risk: past gains don't guarantee future returns.
#DailyLearn#NASDAQ
SM Energy's 82% surge and cheap 4.3x P/E signal near-term bullish momentum, but energy stocks are volatile.
Buy dips.
Risk: oil prices and sector swings.
#NYSE
Ground transport earnings mixed in Q1.
HTLD shines on efficiency.
Macro headwinds: slowing consumer spend & fuel costs.
Cautious on cyclicals.
Long HTLD, short weak players like ULH.
Risk: deeper recession.
#Macro#Earnings#NASDAQ
APRE: Selling stockholders file to resell up to 5.5M shares.
Near-term overhang.
Short-term bias: BEARISH.
Key support $0.77 (1M low).
Wait for volume to absorb supply.
Risk: biotech rallies can defy filings.